Guerbet S.A.

Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
  • TickerGBT
  • ISINFR0000032526
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Pierre Vaurice

GUERBET. CA T3 2019. Accélération organique sur le T3

GUERBET. CA T3 2019. Accélération organique sur le T3

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 10/25/2019

...

Christophe-Raphaël Ganet

Guerbet : CA T3 2019 : légèrement au-dessus de nos attentes (FX favorable) – Guidances maintenues

>Un T3 conforme à la guidance (« croissance modérée » ) - Le CA T3 a atteint 202.9M€ (+5.8% et +3%e à tcc.). A 9M, les ventes ressortent à 603.5 M€ (ODDO : 599.2 M€) +3.8% et +2.2% en tcc. Cette évolution a été alimentée en partie par un effet de change favorable sur le dollar à 9.2 M€, mais contrebalancée par un impact défavorable liée à des contrats de sous-traitance hérités de l’activité CMDS de l’ordre de 5 M€ sur le S2 (cf. notre commentaire du 25/07). ...

Christophe-Raphaël Ganet

Guerbet : Q3 2019 sales: slightly better than we expected (favourable FX impact) – Guidance targets reiterated

>Q3 in line with the guidance (“moderate sales growth”) - Sales came to € 202.9m in Q3 (+5.8% and +3%e at constant currencies). This put 9M sales at € 603.5m (Oddo: € 599.2m), +3.8% and +2.2% cc. The momentum was partly driven by a favourable dollar effect of € 9.2m, but this was offset by a negative impact resulting from subcontracting activities inherited from CMDS of around € 5m in H2 (see our comment from 25 July). Sales in Europe came out slightly lower...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 25/10/2019

...

Pierre Vaurice

GUERBET. CA T3 2019. Accélération organique sur le T3

GUERBET. CA T3 2019. Accélération organique sur le T3

Christophe-Raphaël Ganet

Guerbet : CA T3 2019 : légèrement au-dessus de nos attentes (FX favorable) – Guidances maintenues

>Un T3 conforme à la guidance (« croissance modérée » ) - Le CA T3 a atteint 202.9M€ (+5.8% et +3%e à tcc.). A 9M, les ventes ressortent à 603.5 M€ (ODDO : 599.2 M€) +3.8% et +2.2% en tcc. Cette évolution a été alimentée en partie par un effet de change favorable sur le dollar à 9.2 M€, mais contrebalancée par un impact défavorable liée à des contrats de sous-traitance hérités de l’activité CMDS de l’ordre de 5 M€ sur le S2 (cf. notre commentaire du 25/07). ...

Christophe-Raphaël Ganet

Guerbet : Q3 2019 sales: slightly better than we expected (favourable FX impact) – Guidance targets reiterated

>Q3 in line with the guidance (“moderate sales growth”) - Sales came to € 202.9m in Q3 (+5.8% and +3%e at constant currencies). This put 9M sales at € 603.5m (Oddo: € 599.2m), +3.8% and +2.2% cc. The momentum was partly driven by a favourable dollar effect of € 9.2m, but this was offset by a negative impact resulting from subcontracting activities inherited from CMDS of around € 5m in H2 (see our comment from 25 July). Sales in Europe came out slightly lower...

Pierre Vaurice

GUERBET - Waiting for 2020 (-)

GUERBET - Waiting for 2020 (-)

Pierre Vaurice

GUERBET - En attendant 2020 (-)

GUERBET - En attendant 2020 (-)

1 director sold

A director at Guerbet sold 1,000 shares at 47.200EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 10/25/2019

...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 25/10/2019

...

Christophe-Raphaël Ganet ...
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Jeremy Garnier
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 09/30/2019

...

Christophe-Raphaël Ganet ...
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Jeremy Garnier
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 30/09/2019

...

Aurelien Sivignon ...
  • Baptiste Lebacq
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Hana Maalej
  • Jean-François Granjon
  • Jeremy Garnier
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 09/26/2019

...

GUERBET sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of GUERBET (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date August 30, 2019, the closing price was EUR 48.85 and its target price was estimated at EUR 41.69.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Charles Pinel

Guerbet SA - Assemblée Générale des actionnaires du 24 mai 2019

Le conseil d'administration ne comprendra plus de dirigeant car le mandat d'administrateur du Directeur Général qui arrive à échéance n'est pas renouvelé. Il comprendra donc 10 membres contre 11 précédemment mais il est toujours composé d'une majorité de membres non libres de conflits d'intérêts potentiels, ce qui ne permet pas d'approuver le renouvellement d'un membre de la famille Guerbet, d'autant plus que cette famille est en sur-représentation avec 60% des sièges du conseil pour 53% du capital (résolution 13). Comme chaque année, les politiques de rémunération des dirigeants mandataires ...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch